• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Sun Pharma Advanced Research Company Limited — Board Meeting, 09-02-2026: Outcome of Board Meeting

    09-02-2026 | 05:03 pm

    SPARC's board approved Q3 & 9M consolidated results. The company reported a ₹80.42 Cr Q3 loss and ₹208.14 Cr 9M loss, including a ₹12.36 Cr exceptional cost. Big news: US FDA granted a valuable Rare Pediatric Disease Priority Review Voucher for Sezaby®.

    No comments yet. Be the first to comment!

    All announcements from Sun Pharma Advanced Research Company Limited